Cargando…

QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy

BACKGROUND: Several antipsychotic agents are known to prolong the QT interval in a dose dependent manner. Corrected QT interval (QTc) exceeding a threshold value of 450 ms may be associated with an increased risk of life threatening arrhythmias. Antipsychotic agents are often given in combination wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sala, Michela, Vicentini, Alessandro, Brambilla, Paolo, Montomoli, Cristina, Jogia, Jigar RS, Caverzasi, Eduardo, Bonzano, Alberto, Piccinelli, Marco, Barale, Francesco, De Ferrari, Gaetano M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1088007/
https://www.ncbi.nlm.nih.gov/pubmed/15845138
http://dx.doi.org/10.1186/1744-859X-4-1
_version_ 1782123845713395712
author Sala, Michela
Vicentini, Alessandro
Brambilla, Paolo
Montomoli, Cristina
Jogia, Jigar RS
Caverzasi, Eduardo
Bonzano, Alberto
Piccinelli, Marco
Barale, Francesco
De Ferrari, Gaetano M
author_facet Sala, Michela
Vicentini, Alessandro
Brambilla, Paolo
Montomoli, Cristina
Jogia, Jigar RS
Caverzasi, Eduardo
Bonzano, Alberto
Piccinelli, Marco
Barale, Francesco
De Ferrari, Gaetano M
author_sort Sala, Michela
collection PubMed
description BACKGROUND: Several antipsychotic agents are known to prolong the QT interval in a dose dependent manner. Corrected QT interval (QTc) exceeding a threshold value of 450 ms may be associated with an increased risk of life threatening arrhythmias. Antipsychotic agents are often given in combination with other psychotropic drugs, such as antidepressants, that may also contribute to QT prolongation. This observational study compares the effects observed on QT interval between antipsychotic monotherapy and psychoactive polytherapy, which included an additional antidepressant or lithium treatment. METHOD: We examined two groups of hospitalized women with Schizophrenia, Bipolar Disorder and Schizoaffective Disorder in a naturalistic setting. Group 1 was composed of nineteen hospitalized women treated with antipsychotic monotherapy (either haloperidol, olanzapine, risperidone or clozapine) and Group 2 was composed of nineteen hospitalized women treated with an antipsychotic (either haloperidol, olanzapine, risperidone or quetiapine) with an additional antidepressant (citalopram, escitalopram, sertraline, paroxetine, fluvoxamine, mirtazapine, venlafaxine or clomipramine) or lithium. An Electrocardiogram (ECG) was carried out before the beginning of the treatment for both groups and at a second time after four days of therapy at full dosage, when blood was also drawn for determination of serum levels of the antipsychotic. Statistical analysis included repeated measures ANOVA, Fisher Exact Test and Indipendent T Test. RESULTS: Mean QTc intervals significantly increased in Group 2 (24 ± 21 ms) however this was not the case in Group 1 (-1 ± 30 ms) (Repeated measures ANOVA p < 0,01). Furthermore we found a significant difference in the number of patients who exceeded the threshold of borderline QTc interval value (450 ms) between the two groups, with seven patients in Group 2 (38%) compared to one patient in Group 1 (7%) (Fisher Exact Text, p < 0,05). CONCLUSIONS: No significant prolongation of the QT interval was found following monotherapy with an antipsychotic agent, while combination of these drugs with antidepressants caused a significant QT prolongation. Careful monitoring of the QT interval is suggested in patients taking a combined treatment of antipsychotic and antidepressant agents.
format Text
id pubmed-1088007
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-10880072005-05-02 QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy Sala, Michela Vicentini, Alessandro Brambilla, Paolo Montomoli, Cristina Jogia, Jigar RS Caverzasi, Eduardo Bonzano, Alberto Piccinelli, Marco Barale, Francesco De Ferrari, Gaetano M Ann Gen Psychiatry Primary Research BACKGROUND: Several antipsychotic agents are known to prolong the QT interval in a dose dependent manner. Corrected QT interval (QTc) exceeding a threshold value of 450 ms may be associated with an increased risk of life threatening arrhythmias. Antipsychotic agents are often given in combination with other psychotropic drugs, such as antidepressants, that may also contribute to QT prolongation. This observational study compares the effects observed on QT interval between antipsychotic monotherapy and psychoactive polytherapy, which included an additional antidepressant or lithium treatment. METHOD: We examined two groups of hospitalized women with Schizophrenia, Bipolar Disorder and Schizoaffective Disorder in a naturalistic setting. Group 1 was composed of nineteen hospitalized women treated with antipsychotic monotherapy (either haloperidol, olanzapine, risperidone or clozapine) and Group 2 was composed of nineteen hospitalized women treated with an antipsychotic (either haloperidol, olanzapine, risperidone or quetiapine) with an additional antidepressant (citalopram, escitalopram, sertraline, paroxetine, fluvoxamine, mirtazapine, venlafaxine or clomipramine) or lithium. An Electrocardiogram (ECG) was carried out before the beginning of the treatment for both groups and at a second time after four days of therapy at full dosage, when blood was also drawn for determination of serum levels of the antipsychotic. Statistical analysis included repeated measures ANOVA, Fisher Exact Test and Indipendent T Test. RESULTS: Mean QTc intervals significantly increased in Group 2 (24 ± 21 ms) however this was not the case in Group 1 (-1 ± 30 ms) (Repeated measures ANOVA p < 0,01). Furthermore we found a significant difference in the number of patients who exceeded the threshold of borderline QTc interval value (450 ms) between the two groups, with seven patients in Group 2 (38%) compared to one patient in Group 1 (7%) (Fisher Exact Text, p < 0,05). CONCLUSIONS: No significant prolongation of the QT interval was found following monotherapy with an antipsychotic agent, while combination of these drugs with antidepressants caused a significant QT prolongation. Careful monitoring of the QT interval is suggested in patients taking a combined treatment of antipsychotic and antidepressant agents. BioMed Central 2005-01-25 /pmc/articles/PMC1088007/ /pubmed/15845138 http://dx.doi.org/10.1186/1744-859X-4-1 Text en Copyright © 2005 Sala et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Primary Research
Sala, Michela
Vicentini, Alessandro
Brambilla, Paolo
Montomoli, Cristina
Jogia, Jigar RS
Caverzasi, Eduardo
Bonzano, Alberto
Piccinelli, Marco
Barale, Francesco
De Ferrari, Gaetano M
QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy
title QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy
title_full QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy
title_fullStr QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy
title_full_unstemmed QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy
title_short QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy
title_sort qt interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1088007/
https://www.ncbi.nlm.nih.gov/pubmed/15845138
http://dx.doi.org/10.1186/1744-859X-4-1
work_keys_str_mv AT salamichela qtintervalprolongationrelatedtopsychoactivedrugtreatmentacomparisonofmonotherapyversuspolytherapy
AT vicentinialessandro qtintervalprolongationrelatedtopsychoactivedrugtreatmentacomparisonofmonotherapyversuspolytherapy
AT brambillapaolo qtintervalprolongationrelatedtopsychoactivedrugtreatmentacomparisonofmonotherapyversuspolytherapy
AT montomolicristina qtintervalprolongationrelatedtopsychoactivedrugtreatmentacomparisonofmonotherapyversuspolytherapy
AT jogiajigarrs qtintervalprolongationrelatedtopsychoactivedrugtreatmentacomparisonofmonotherapyversuspolytherapy
AT caverzasieduardo qtintervalprolongationrelatedtopsychoactivedrugtreatmentacomparisonofmonotherapyversuspolytherapy
AT bonzanoalberto qtintervalprolongationrelatedtopsychoactivedrugtreatmentacomparisonofmonotherapyversuspolytherapy
AT piccinellimarco qtintervalprolongationrelatedtopsychoactivedrugtreatmentacomparisonofmonotherapyversuspolytherapy
AT baralefrancesco qtintervalprolongationrelatedtopsychoactivedrugtreatmentacomparisonofmonotherapyversuspolytherapy
AT deferrarigaetanom qtintervalprolongationrelatedtopsychoactivedrugtreatmentacomparisonofmonotherapyversuspolytherapy